Glycoprotein Iib Iiia
Mostrando 1-12 de 102 artigos, teses e dissertações.
-
1. Bilateral subconjunctival hemorrhage secondary to abciximab use: case report
ABSTRACT CONTEXT: There are no reports on cases of subconjunctival hemorrhage due to use of glycoprotein IIb/IIIa inhibitors. In this report, we present the case of a patient with bilateral subconjunctival hemorrhage after receiving abciximab. CASE REPORT: A 40-year-old male patient underwent coronary angiography after acute anterior myocardial infarctio
Sao Paulo Med. J.. Publicado em: 18/12/2017
-
2. Mecanismo da incubação de enterotoxinas estafilococicas e do lipopolissacaride na agregação e na adesão de plaquetas humanas / Incubation effects of staphylococcal enterotoxins and lipopolysaccharide in human platelets aggregation and adhesion
Sepsis is the second major cause of death in intensive care unit. Septic patients show abnormalities in platelet like thrombocytopenia, prolongation in coagulation time, disseminated intravascular coagulation, deep venous thrombosis and bleedings. However, the mechanisms involved in these platelet alterations are not totally clear. The objective of this work
Publicado em: 2008
-
3. FunÃÃo plaquetÃria e o antÃgeno do fator de von Willebrand na forma hepatoesplÃnica da esquistossomose mansoni
Com o objetivo de se verificar a existÃncia de alteraÃÃes da morfologia plaquetÃria, de seus antÃgenos de superfÃcie, da agregaÃÃo das plaquetas e da dosagem do antÃgeno do Fator de von Willebrand (FvW:Ag) em portadores de esquistossomose mansÃnica na sua forma hepatoesplÃnica compensada, foram estudados 45 indivÃduos, adultos, entre 22 a 83 anos
Publicado em: 2007
-
4. "Análise volumétrica da hiperplasia intimal intra-stent em pacientes diabéticos tratados com e sem abciximab" / Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab
Ninety-six type 2 diabetics were randomly assigned to receive abciximab or no abciximab at the time of elective stent implantation to determine whether this IIb/IIIa glycoprotein inhibitor would reduce in-stent intimal hyperplasia, measured by intravascular ultrasound, at 6-month follow-up. Volumetric analysis showed that abciximab was not associated with a
Publicado em: 2004
-
5. Concomitant Use of Glycoprotein IIb/IIIa Inhibitor and Streptokinase after Unsuccessful Rescue Angioplasty
A 38-year-old man with acute myocardial infarction in the lower wall affecting the right ventricle underwent thrombolytic treatment with streptokinase. Approximately 2 hours after the thrombolytic treatment started, he presented with signs of coronary reocclusion. He underwent emergency cineangiocoronariography that revealed that his right coronary artery wa
Arquivos Brasileiros de Cardiologia. Publicado em: 2002-04
-
6. Contribution to the investigation of hemostatic disturbances induced by Bothrops jararaca snake venom in rabbits: study of platelet membrane glycoproteins, function, secretion and survival. / Contribuição à investigação das alterações hemostáticas induzidas pelo veneno da serpente Bothrops jararaca em coelhos: estudo das glicoproteínas da membrana, função, secreção e sobrevivência plaquetárias.
Que o envenenamento pela serpente Bothrops jararaca causa distúrbios hemorrágicos sistêmicos, com alteração da coagulação e fibrinólise sangüíneas, é notório. Contudo, pouco se sabe sobre a ação in vivo desse veneno sobre as plaquetas. Em estudos recentes, demonstrou-se que esse veneno causa trombocitopenia, distúrbios da agregação e diminui
Publicado em: 2002
-
7. Glycoprotein IIb-IIIa and the translocation of Rap2B to the platelet cytoskeleton.
The stimulation of human platelets with physiological agonists results in the incorporation of several proteins into the cytoskeleton, fibrinogen binding, and platelet aggregation. We recently demonstrated that the Ras-related low molecular weight GTP-binding protein Rap2B associates with the cytoskeleton in activated platelets and that this interaction requ
-
8. Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
Aspirin has stood the test of time over decades as the gold standard for relatively effective, safe, and inexpensive antiplatelet therapy. However, aspirin is only modestly effective in preventing arterial thrombosis in certain settings, and it is virtually ineffective in others (for example, preventing coronary restenosis after angioplasty). These observati
-
9. Synthesis of analogs of human platelet membrane glycoprotein IIb-IIIa complex by chicken peripheral blood thrombocytes.
Human platelets and their phylogenetic counterparts, avian thrombocytes, play a key role in primary hemostasis. Based upon extensive studies in mammals, platelet cohesion resulting in the formation of the "hemostatic plug" is known to be mediated by the mammalian platelet glycoprotein IIb-IIIa complex in concert with fibrinogen and calcium. The immunological
-
10. Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation.
Von Willebrand factor (vWF) was purified from the plasma of a patient with type IIB von Willebrand disease (vWF from such a patient, IIB vWF) who had a normal platelet count and showed no evidence of spontaneous platelet aggregation. Large multimers of IIB vWF were absent from purified preparations and from plasma. Ristocetin-induced platelet aggregation was
-
11. A variant of Glanzmann's thrombasthenia with abnormal glycoprotein IIb-IIIa complexes in the platelet membrane.
Patient C.M. presented platelet function defects symptomatic of Glanzmann's thrombasthenia. However, analysis of surface-labeled platelets by SDS-polyacrylamide gel electrophoresis revealed the usual presence of the major glycoproteins, including GP IIb and GP IIIa. Platelet fibrinogen was not detected. Analysis of Triton X-100 extracts of Ca2+-washed C.M. p
-
12. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms. In this review, we present a systematic overview of these
BioMed Central.